This site is intended for health professionals only!

Published on 26 June 2014

Share this story:

Actavis launches Moxifloxacin

Moxifloxacin tablets are now available from Actavis, following the patent expiry of Avelox.
This launch further strengthens Actavis’ portfolio of over 750 generic medicines across a wide variety of therapy areas.
Moxifloxacin is indicated for the treatment of acute bacterial sinusitis, acute exacerbations of chronic bronchitis, community-acquired pneumonia (except in severe cases) and mild to moderate pelvic inflammatory disease.

Moxifloxacin tablets are now available from Actavis, following the patent expiry of Avelox.
This launch further strengthens Actavis’ portfolio of over 750 generic medicines across a wide variety of therapy areas.
Moxifloxacin is indicated for the treatment of acute bacterial sinusitis, acute exacerbations of chronic bronchitis, community-acquired pneumonia (except in severe cases) and mild to moderate pelvic inflammatory disease.
Moxifoxacin may also be used to complete a course of therapy for patients who have shown improvement during treatment with intravenous moxifloxacin for community-acquired pneumonia and complicated skin infections.
Actavis is offering 400 mg Moxifloxacin tablets in, packs of five. All products are available through major wholesalers or directly from the Actavis Telemarketing team on freephone: 0800 731 0370 or fax: 0800 731 0380.
Jonathan Wilson, Executive Director UK, commented: “This is the second patent expiry in as many months where Actavis have bought high quality pharmaceuticals to market on day one. Actavis has a successful track record of day one releases, as well as a history of offering significant savings and a reliable supply chain.”



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine